Alfred Ford, Jr. Sells 6,275 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 6,275 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.09, for a total value of $151,164.75. Following the sale, the insider owned 99,564 shares of the company’s stock, valued at $2,398,496.76. This trade represents a 5.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 0.8%

KMTS traded up $0.21 on Thursday, hitting $25.27. The company had a trading volume of 184,867 shares, compared to its average volume of 393,651. The stock has a fifty day moving average price of $22.86 and a 200-day moving average price of $22.54. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. On average, equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of KMTS. Price T Rowe Associates Inc. MD raised its position in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after buying an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the last quarter. Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares during the last quarter.

Wall Street Analyst Weigh In

KMTS has been the subject of several analyst reports. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, BTIG Research raised their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.